Use of Flumazenil in the Production of a Drug for the Treatment of Alcohol Dependency

Abstract

The invention relates to the use of flumazenil in developing a drug used for the sequential administration of small quantities of flumazenil at short intervals, until a therapeutically effective quantity is administered to treat alcohol dependence.

Description

FIELD OF THE INVENTION[0001]The invention relates to the use of pharmaceutical compositions that contain flumazenil in the treatment of alcohol dependency, more specifically to improvements in the use of flumazenil in the treatment of said dependency.BACKGROUND OF THE INVENTION[0002]Alcohol dependency is a syndrome that develops in alcoholics who, all at once, stop consuming alcohol. Minor symptoms include tremor, weakness, sweats, and nausea. The most severe cases include convulsions and hallucinations. If untreated, alcohol withdrawal may cause delirium tremens.[0003]The customary treatment of alcohol dependency includes the administration of vitamin B and C complexes, benzodiazepines (to calm agitation and to help prevent dependency), and, sometimes disulfiram (to prevent alcohol use). A review of the various pharmacological treatments existing for the treatment of alcohol dependency can be found in A Practice Guideline for the Treatment of Patients With Substance Use Disorders: ...

AI Technical Summary

Benefits of technology

"The invention is about a new way to treat alcohol dependence using a drug called flumazenil. The method involves giving small amounts of flumazenil sequentially over a short period of time to quickly reduce the symptoms of alcohol withdrawal. This approach reduces the side effects of giving a large amount of flumazenil all at once and ensures that the drug is effective and safe. The invention also includes the use of pharmaceutical compositions containing small amounts of flumazenil that can be administered sequentially to treat alcohol dependence."

Problems solved by technology

If untreated, alcohol withdrawal may cause delirium tremens.

Moreover, Gerra et al. do not present data concerning the evaluation of the dependency either before or after administration of the drug.

The treatment with flumazenil, in accordance with the protocol developed by Gerra et al., lasts 4 days, which means a very long period of time which causes inconvenience for the patient as well as an increase in the cost and duration of the treatment.

The results obtained after the administration of flumazenil were not completely satisfactory since in some cases, there was an immediate worsening of the withdrawal symptoms, especially of sweats and anxiety.

Since flumazenil is metabolized and eliminated very quickly, the IV administration of a relatively high quantity of fumazenil in a single dose of 2 mg, for 1 minute, has several disadvantages since, on the one hand, it triggers side effects, and, on the other, some of the flumazenil administered yields no pharmacological response or a weak response which means an unacceptable expense.

The tests performed by Gerra et al. and by Nutt et al., loc. cit., with flumazenil to treat alcohol dependency do not provide representative results due to the use of a very small sample (only 19 patients tested of the approximately 600,000 patients treated annually in the United States during the years 1991-1994, years during which the work of Gerra et al. and of Nutt et al. occurred) which is not representative of said patients (the 11 patients treated in the trial of Gerra et al. were selected alcoholics who did not have cirrhosis, metabolic disorders, convulsions, addictions to other substances or psychiatric disord

ers). Moreover, the results obtained are not conclusive since in some cases, no significant changes were observed in either the blood pressure or the heart rate of patients after the administration of flumazenil (Gerra et al., loc.